

AeroEclipse® II

Breath Actuated Nebulizer



Ordering Information		
Part Number	Description	Case Size
10550191050	AeroEclipse® II BAN with Mouthpiece, Supply Tubing and patient instructions	Case of 50

Product Specifications

Feature	AeroEclipse® II
Reorder Number – Case of 50 units (Includes: AeroEclipse® II BAN, mouthpiece, supply tubing, patient instruction sheet)	10550191050 Size: Package (Single Unit) 26cm x 100cm x 6cm (10.5" x 7" x 2") Carton (50/Box) 50cm x 26cm x 40cm (19.5" x 10" x 15.5") Weight: Package (Single Unit) 82 grams (0.18lbs) Carton (50/Box) 4.54 kg (10lbs)
Delivery Method	Spontaneous Breathing
Nebulizing Method	Breath Actuated or Continuous Mode
Actuation Flow Rate	15 lpm
Fill Lines	External molded: 0.5 ml to 6 ml Internal molded: 1 ml
Operating Flow Rate	7 – 8 lpm, 50 psi
Air Entrainment	Yes – through the top
Visual Actuation Feedback Indicator	Yes
Drool Guard	Yes
Latex Free	Yes
Removable Mouthpiece	Yes
Operating Angle	Up to 45 degrees

Aerosol Performance

Fine Particle Fraction* (% < 4.8 microns)	78.4 %
Mass Median Aerodynamic Diameter* (MMAD)	2.8 µm
Breath Actuated Mode* (2.5mg albuterol, UD)	Respirable Dose to Sputter 791 µg Respirable Dose per Minute 97 µg
Breath Actuated Mode (2.5mg albuterol, 0.5ml/0.5ml)	Respirable Dose to Sputter 568 µg Respirable Dose per Minute 298 µg
Continuous Mode*	Respirable Dose to Sputter 378 µg
Environmental Aerosol* Emissions (3.0ml UD albuterol)	Breath Actuated Mode 4 %

* TMI Aerosol Lab, Data on File: 3.0ml Albuterol Solution 0.83mg/ml, 8 L/min 50psi, tidal volume 0.6L, rate 100rpm, 33% duty cycle as inhalation

THE MOST SIGNIFICANT ADVANCEMENT

in the history of small volume nebulizers



The Benefits of a Breath Actuated Nebulizer (BAN)

- Virtually no aerosol is produced during expiration
- Clinical dose assurance
- Environmental protection for caregivers and healthcare providers
- Less wasted medication

Ultimate dose assurance of inhaled aerosol that may provide a safer healthcare and patient environment.^{1,2}

AeroEclipse® II

Breath Actuated Nebulizer

Confidence in aerosol delivery



Trudell Medical International¹

Contact Information:

Trudell Medical International
725 Third Street, London,
Ontario, Canada, N5V 5G4
Phone: +1-519-455-7060
Fax: +1-519-455-7858

Email: customerservice@trudellmed.com
www.trudellmed.com



Canadian Hospital Distribution:

Trudell Medical Marketing Limited
758 Third Street, London, Ontario,
Canada N5V 5J7
Email: tmml@tmml.com
Web site: www.tmml.com

Authorised European Representative:

Trudell Medical International Europe Ltd.
BioCity Nottingham, Pennyfoot Street
Nottingham, NG1 1GF, UK
Email: customerservice@trudellmed.com

References:


- 1 Respiratory Therapists Twice as Likely to Have Asthma Than Other Therapists – Exposure to Patient Treatments May Increase Therapists' Asthma Risk, Canadian Society of Respiratory Therapists News, Oct. 2004.
- 2 Camathran B, Martin B, Colice G. Second Hand (S)-Albuterol: RT Exposure Risk Following Racemic Albuterol. Respiratory Care, October 2001, Vol. 46, No. 10.
- 3 TMI Aerosol Lab, Data on File: 3.0ml albuterol solution 0.83mg/ml, 8L/min, 50psi, tidal volume 600 ml, Rate 100rpm, 33% duty cycle as inhalation (breath actuation mode).

Superior, Assured Aerosol Performance with the **AeroEclipse® II BAN**

AeroControl® System Regulator
Patented diaphragm and grid system enhances actuation sensitivity to only 15 lpm of inspiratory effort to trigger the device

One-Way Exhalation Valve
Virtually eliminates the mixing of inspirate and expirite

— Supplied Air
— Entrained Air
— Aerosol



Green Feedback Button
Signals actuation and provides a visual assist to proper use and breathing technique

Air Entrainment
Improves delivery of fine particle mass

Breath Actuated Nebulizer

Mode Selector
Convenient selection of operational modes

Top View




Breath Actuated Mode
Continuous Mode



AeroEclipse® II **Breath Actuated Nebulizer** Confidence in aerosol delivery

When using the AeroEclipse® II BAN
titrate to the lowest dose at which effective control can be maintained.


Fine Particle Dose³ – Albuterol



Less Drug Exposure from the AeroEclipse® II BAN

"It is important for respiratory therapists and other medical professionals to recognize and understand the possible respiratory effects related to the administration of aerosolized substances and take appropriate steps to minimize their exposure to these medications during patient diagnostic procedures and treatments."¹

Fugitive Emissions³ – Albuterol



³ Mass loss includes drug that escaped from the nebulizer to the surrounding atmosphere together with trace amounts left behind in the ampoule